作者
Anurag Mehta, Steven P Marso, IJ28392927 Neeland
发表日期
2017/3
来源
Obesity science & practice
卷号
3
期号
1
页码范围
3-14
简介
Objective
To review the efficacy, safety, and clinical applicability of liraglutide for weight management from phase III clinical trials.
Methods
A search of the English language literature was performed using PubMed search terms: “liraglutide”, “glucagon‐like peptide‐1 receptor agonist”, and “randomized clinical trial”. Articles and bibliographies relevant to the subject were reviewed and additional references known to the authors were included.
Results
Five randomized, placebo‐controlled trials of liraglutide for weight management were identified. In addition to recommended diet and physical activity, liraglutide consistently resulted in a 4 to 6 kg weight loss, with a greater proportion of patients achieving at least 5 and 10% weight loss compared with placebo. The most common adverse effects were gastrointestinal and primarily occurred early in the treatment course. Comparative data suggest that weight loss with …
引用总数
2016201720182019202020212022202320241318415246425823